Thursday, May 23, 2013
Publication and contact
Classification system for
In vitro studies were used to develop a classification
system for endometrial cancers that could help guide treatment regimens for
patients after initial therapy. Endometrial cancers are traditionally divided
into the endometrioid and serous subtypes, with favorable and poor prognoses,
respectively. In 373 samples from patients who have endometrial carcinoma,
genome, proteome and transcriptome analyses were used to subdivide the
cancers into four categories based on high or low levels of somatic copy
number variants (CNVs), mutation status of DNA-directed
DNA polymerase e (POLE)
and microsatellite instability. Genetic analysis showed that high somatic
CNVs correlated with a poor prognosis independent of subtype classification.
Next steps could include determining whether there is a relationship between
the identified disease subtypes and treatment response.
Published online May 23, 2013
Patent and licensing status
Cancer Genome Atlas
Research Network. Nature; published online May 1, 2013;
Contact: Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]